The objective of this study was to assess whether adding CAN-2409 in combination with the prodrug valacyclovir to standard of care radiation therapy could improve the proportion of patients achieving ...

Annual Congress, CureGene Pharmaceuticals ("CureGene") announced late-breaking preclinical results for its investigational liver-targeted thyroid hormone receptor beta (THR-β) prodrug, CG-0416.

May 14, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides that drive the production of ...

In the 10-Q report, ZEVRA THERAPEUTICS, INC. discussed its financial condition and results of operations. The company reported net proceeds of $148.3 million from the sale of a transferable rare ...

GEN2 is well tolerated with minimal toxicity and signs of pharmacodynamic activity in an ongoing Phase 1 dose escalation and ...

Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 ...

Department of Pharmaceutical Chemistry, University of Kuopio, PO Box 1627, FI-70211 Kuopio, Finland, Department of Pharmacology and Toxicology, University of Kuopio, PO Box 1627, FI-70211 Kuopio, ...

Expert Rev Clin Pharmacol. 2012;5(3):319-336. Finally, a recent study suggested that although prasugrel significantly reduces thrombotic events in patients with ACS undergoing PCI because of its ...

GeoVax Reveals Promising Results for Gedeptin® Cancer Therapy at AACR Annual Meeting GeoVax Reveals Promising Results for Gedeptin® Cancer Therapy at AACR Annual Meeting April 29th, 2025 4:00 PM By: ...

As­traZeneca’s Truqap is 2-for-4 in its piv­otal can­cer tri­als. It said it was shut­ting down a Phase 3 Truqap study in … ...

The candidate is a prodrug of riluzole, which is already approved for amyotrophic lateral sclerosis (ALS). Troriluzole is being evaluated for SCA, a rare neurodegenerative disorder with limited ...